Small molecule · Inhibitor of farnesyl transferase (FNTA) and geranylgeranyl transferase (PGGT1B) · developed by Neonc Technologies
Perillyl alcohol (NEO100) is a naturally occurring monoterpene related to limonene. It inhibits farnesyl transferase and geranylgeranyl transferase, preventing protein farnesylation and isoprenylation and activation of oncoproteins such as p21-ras, and arresting tumor cells in the G1 phase. It is studied in glioblastoma multiforme and grade II or III meningioma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05023018 | Phase 2 | Residual, Progressive or Recurrent Grade II or III Meningioma | Recruiting | NTHI |
| NCT02704858 | Phase 1/2 | Glioblastoma Multiforme | Active not recruiting | NTHI |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Glioblastoma Multiforme
Updated Oct 25, 2026. Something wrong or missing? Report it on the NTHI page.
See NTHI's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NTHI catalysts and pipeline →